HIMS & HERS Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Increased nearly 40% year-over-year to over $753 million, with domestic revenue growing 16% year-over-year to $622 million.

Subscribers: Added 300,000 net new subscribers, bringing the total to nearly 3 million.

Adjusted EBITDA: Reported at $60 million, representing an 8% margin, with a one-point improvement quarter-over-quarter.

Gross Margin: Declined to 64%, down approximately 6 points quarter-over-quarter due to a shift towards branded weight loss products and international revenue.

Net Income: Reported a GAAP net loss of $86 million, impacted by nonrecurring costs related to acquisitions and legal matters.

Cash Position: Ended the quarter with over $840 million in cash and short-term investments.

2Strategic Updates and Business Highlights

AI Investment: Significant focus on integrating AI into the platform, enhancing customer engagement and operational efficiencies, with a 50% reduction in nonclinical tasks handled by support teams.

Global Expansion: Acquisition of Eucalyptus expanded international presence, contributing approximately $40 million in revenue. International revenue increased over 17-fold year-over-year to $131 million.

New Offerings: Successful launch of testosterone therapy, expected to reach a $100 million annual run rate soon. Development of a peptide therapy program is underway, pending FDA guidance.

Partnerships: Strengthened collaboration with Novo Nordisk, enhancing access to weight loss treatments and improving retention rates.

3Forward Guidance and Outlook

Q3 2026 Revenue Guidance: Expected to be between $880 million and $900 million, representing a year-over-year increase of approximately 47% to 50%.

Full Year 2026 Revenue Outlook: Raised to $3.1 billion to $3.3 billion, indicating a year-over-year increase of 32% to 41%.

Adjusted EBITDA for 2026: Expected to be between $275 million and $325 million, with a margin of approximately 9% at the midpoint.

4Bad News, Challenges, or Points of Concern

Legal Issues: Ongoing litigation with the FTC could pose risks, with costs impacting financials.

Gross Margin Compression: Continued decline in gross margins expected due to the mix shift towards lower-margin weight loss products and international revenue.

Cash Flow: Negative operating cash flow of $36 million in Q2 due to increased working capital demands; however, the expectation is to return to positive cash flow in the second half of the year.

Market Competition: The need to maintain competitive advantages in a rapidly evolving health tech landscape, especially as AI becomes more commoditized.

5Notable Q&A Insights

Peptide Market Readiness: The company is prepared to launch peptide therapies quickly once FDA guidance is received, with ongoing preparations in place.

AI Integration: The AI strategy is initially focused on the women’s weight loss segment, with plans to expand to other areas, enhancing customer engagement and retention.

Eucalyptus Contribution: Eucalyptus is expected to operate near breakeven, with potential for growth as domestic operations strengthen.

Retention Rates: Improved retention rates observed in weight loss cohorts, attributed to enhanced customer experience through AI tools and immersive offerings. This summary encapsulates Hims & Hers' financial performance, strategic initiatives, and outlook while addressing potential challenges and insights from the Q&A session.